How India Exports Hydrochlorothiazide to the World

In the United States, Hydrochlorothiazide has been a staple in hypertension treatment since its initial approval. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for Hydrochlorothiazide, indicating a robust generic market. The first ANDA approval dates back to January 24, 1975, for Danbury Pharmacal's 25 mg tablets. Given the substantial volume of Hydrochlorothiazide exports from India to the U.S., it is evident that Indian manufacturers play a significant role in supplying the American market. The absence of current import alerts related to Hydrochlorothiazide underscores compliance with FDA standards. The regulatory pathway for Hydrochlorothiazide involves the submission of an ANDA, demonstrating bioequivalence to the reference listed drug, thereby facilitating market entry for generic versions.

Within the European Union, Hydrochlorothiazide is often marketed in combination with other antihypertensive agents. For instance, the European Medicines Agency (EMA) approved CoAprovel, a combination of irbesartan and hydrochlorothiazide, on October 14, 1998, for the treatment of essential hypertension. (ema.europa.eu) Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized various Hydrochlorothiazide-containing products. Manufacturers exporting to these regions must adhere to Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA, ensuring product quality and safety.

Hydrochlorothiazide is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also subject to international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, Hydrochlorothiazide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Hydrochlorothiazide is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

The primary patents for Hydrochlorothiazide have long expired, leading to a competitive generic market. This patent expiration has facilitated the entry of multiple manufacturers, including Indian exporters, into global markets without the constraints of patent infringement.

In the past 12 months, several notable developments have occurred:

1. API Price Fluctuations: In June 2025, the Indian Ministry of Chemicals and Fertilizers reported a 5% increase in the price of Active Pharmaceutical Ingredients (APIs) for Hydrochlorothiazide, attributed to rising raw material costs.

2. Regulatory Approvals: In September 2025, the FDA approved a new generic version of Hydrochlorothiazide 25 mg tablets manufactured by an Indian pharmaceutical company, further expanding the market presence of Indian exporters.

3. Policy Changes: In December 2025, the NPPA announced a review of the DPCO list, considering the inclusion of additional antihypertensive drugs, which may impact future pricing regulations for Hydrochlorothiazide.

These developments highlight the dynamic nature of the pharmaceutical industry and the importance of staying abreast of regulatory and market changes.

Hydrochlorothiazide, a widely used diuretic, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) and intermediates sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in October 2025.

The COVID-19 pandemic in 2020 exposed the vulnerabilities of this supply chain. Disruptions in Chinese manufacturing led to significant shortages of essential APIs, including those for hydrochlorothiazide. This event underscored the risks associated with over-reliance on a single country for critical raw materials. Despite efforts to diversify sources, the structural dependency on Chinese KSMs persists, posing ongoing risks to the stability of hydrochlorothiazide production.

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in the export of hydrochlorothiazide from India. The top five exporters account for 83.1% of the total export value, with UNICHEM LABORATORIES LIMITED alone contributing 60.8%. This concentration heightens the risk of supply disruptions, as any operational issues within these key companies could significantly impact global availability.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic production of critical APIs and KSMs. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA. While these initiatives are steps toward reducing import dependence, their impact on hydrochlorothiazide's supply chain remains limited, given the drug's specific raw material requirements.

Geopolitical tensions and maritime disruptions have further complicated the supply chain for hydrochlorothiazide. In March 2026, escalating freight charges and supply chain issues threatened India's pharmaceutical exports to the Middle East, with potential losses estimated between ₹2,500 crore to ₹5,000 crore. Key markets like the UAE, Saudi Arabia, and Oman, which are highly dependent on Indian generic medicines, faced significant risks.

Additionally, the U.S. Food and Drug Administration (FDA) has issued alerts regarding drug shortages linked to supply chain vulnerabilities. These alerts emphasize the need for robust risk management strategies to address potential disruptions in the availability of essential medications like hydrochlorothiazide.

• Diversify Raw Material Sources: Encourage the development of alternative suppliers for KSMs and intermediates to reduce dependency on a single country.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical APIs and KSMs through incentives and infrastructure development.

• Strengthen Supplier Relationships: Foster partnerships with multiple suppliers to ensure a more resilient supply chain.

• Implement Advanced Manufacturing Technologies: Adopt continuous manufacturing and flow chemistry to improve production efficiency and flexibility.

• Develop Strategic Stockpiles: Establish reserves of essential APIs and KSMs to buffer against potential supply disruptions.

RISK_LEVEL: HIGH